Mio Tanaka-Yamaguchi

Sendai, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Establishment and Operation of a New Style Clinical Biobank: The Tohoku University Clinical Biobank.

Establishment and Operation of a New Style Clinical Biobank: The Tohoku University Clinical Biobank.

Journal: The Tohoku journal of experimental medicine

Published: January 14, 2026

Artificial Intelligence for Breast Carcinoma Detection in Histopathological Images Based on Single Shot Multibox Detector in Intraoperative Rapid Diagnosis.

Artificial Intelligence for Breast Carcinoma Detection in Histopathological Images Based on Single Shot Multibox Detector in Intraoperative Rapid Diagnosis.

Journal: The Tohoku journal of experimental medicine

Published: December 03, 2025

T-Cell Immunoglobulin and Mucin Domain 1 (Tim1) as a Prognostic Factor Associated With Therapeutic Resistance in Human Breast Carcinoma.

T-Cell Immunoglobulin and Mucin Domain 1 (Tim1) as a Prognostic Factor Associated With Therapeutic Resistance in Human Breast Carcinoma.

Journal: International journal of breast cancer

Published: October 21, 2025

Infiltration of TIM4-positive intratumoral macrophages serves as an adverse prognostic factor in breast cancer.

Infiltration of TIM4-positive intratumoral macrophages serves as an adverse prognostic factor in breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: July 31, 2025

5α-reductase type 3 is a predictive marker for chemotherapy efficacy in breast cancer in an androgen-independent manner.

5α-reductase type 3 is a predictive marker for chemotherapy efficacy in breast cancer in an androgen-independent manner.

Journal: The Journal of steroid biochemistry and molecular biology

Published: April 01, 2025

C-type lectin-like domain family 2 (CLEC2D) promotes proliferation and migration of breast cancer and serves as a poor prognostic factor.

C-type lectin-like domain family 2 (CLEC2D) promotes proliferation and migration of breast cancer and serves as a poor prognostic factor.

Journal: Breast cancer (Tokyo, Japan)

Published: March 19, 2025

Discoidin Domain Receptor 2 (DDR2) Promotes Prostate Cancer Progression in Cooperation with Collagen Remodeling.

Discoidin Domain Receptor 2 (DDR2) Promotes Prostate Cancer Progression in Cooperation with Collagen Remodeling.

Journal: Acta histochemica et cytochemica

Published: February 07, 2025

Discoidin Domain Receptor 2 Contributes to Breast Cancer Progression and Chemoresistance by Interacting with Collagen Type I.

Discoidin Domain Receptor 2 Contributes to Breast Cancer Progression and Chemoresistance by Interacting with Collagen Type I.

Journal: Cancers

Published: December 12, 2024

Regulation of Stromal Cells by Sex Steroid Hormones in the Breast Cancer Microenvironment.

Regulation of Stromal Cells by Sex Steroid Hormones in the Breast Cancer Microenvironment.

Journal: Cancers

Published: October 31, 2024

Receptor for Hyaluronan Mediated Motility (RHAMM)/Hyaluronan Axis in Breast Cancer Chemoresistance.

Receptor for Hyaluronan Mediated Motility (RHAMM)/Hyaluronan Axis in Breast Cancer Chemoresistance.

Journal: Cancers

Published: October 02, 2024

Matrix metalloproteinase-3 is a potent prognostic factor associated with cell proliferation and migration in prostate cancer.

Matrix metalloproteinase-3 is a potent prognostic factor associated with cell proliferation and migration in prostate cancer.

Journal: Experimental and molecular pathology

Published: September 10, 2024

Clinicopathological significance of hyaluronan and hyaluronidase 2 (HYAL2) in breast cancer.

Clinicopathological significance of hyaluronan and hyaluronidase 2 (HYAL2) in breast cancer.

Journal: Pathology, research and practice

Published: April 08, 2024

Showing 1-12 of 16

Last Updated: 09/26/2026